PLX vs TVTX
PLX: A rare-disease biopharmaceutical company with a proprietary plant cell-based protein expression platform and two FDA/EMA-approved enzyme replacement therapies for lysosomal storage disorders. TVTX: Rare kidney disease specialist with two approved FILSPARI formulations (IgAN, FSGS) and a clinical-stage enzyme therapy poised to become the first disease-modifying treatment for homocystinuria.
Side-by-side fundamentals
| Metric | PLX | TVTX | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $2.46 | $61.32 | |
| Market cap as of 2026-08-09 | $198M | $5.8B | |
| P/E as of 2026-08-09 | 12.93 | n/a | |
| PEG as of 2026-08-09 | 0.04 | 1.04 | PLX lower |
| Net margin as of 2026-08-09 | +20.1% | -7.3% | PLX higher |
| Gross margin as of 2026-08-09 | +70.0% | +98.6% | TVTX higher |
| Operating margin as of 2026-08-09 | +25.9% | -6.8% | PLX higher |
| ROE as of 2026-08-09 | +28.1% | -55.8% | PLX higher |
| ROA as of 2026-08-09 | +17.8% | -7.0% | PLX higher |
| Debt / equity as of 2026-08-09 | 0.00 | 24.58 | PLX lower |
| Revenue growth (YoY) as of 2026-08-09 | +27.8% | +77.1% | TVTX higher |
| Revenue CAGR (3y) SEC XBRL | +3.5% | +64.9% | TVTX higher |
| Beta as of 2026-08-09 | -0.10 | 1.10 | |
| 1-year return as of 2026-08-07 close | +62.9% | +262.6% | TVTX higher |
Fundamentals: market data, as of 2026-08-09. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.